SCHEMBL3298281

SCHEMBL3298281

CN(C)CCN1C(=O)c2cccc3cc4c(N)cccc4c(c23)C1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 0.65
CYP2D6 P10635 1/20 0.65
HEXA P06865 2/20 0.62
HEXB P07686 2/20 0.62
PABPC1 P11940 3/20 0.55
POLB P06746 4/20 0.53
NR1I2 O75469 1/20 0.53
AHR P35869 1/20 0.53
RAD52 P43351 1/20 0.53
RCE1 Q9Y256 1/20 0.53
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
NPSR1 Q6W5P4 3/20 0.51
CYP1A2 P05177 1/20 0.51
TNNI3 P19429 1/20 0.51
MAPK1 P28482 1/20 0.51
STAT6 P42226 1/20 0.51
TNNT2 P45379 1/20 0.51
TNNC1 P63316 1/20 0.51
TERT O14746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3295942 0.88 FTO (0.68) FTOCYP2D6HEXAHEXBPABPC1
Azonafide SCHEMBL3804056 0.87 HEXA (0.67) FTOCYP2D6HEXAHEXBPABPC1
Azonafide SCHEMBL29371924 0.87 HEXA (0.67) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL17557121 0.85 FTO (0.70) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL17557147 0.84 FTO (0.66) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL13317024 0.84 HEXA (0.63) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL17557100 0.84 FTO (0.69) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL17557145 0.84 FTO (0.56) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL3298297 0.82 PABPC1 (0.65) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL17557098 0.82 HEXA (0.59) FTOCYP2D6HEXAHEXBPABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160067241-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS BROWN DENNIS M (US) 2016-03-10 US disclosed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 US disclosed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 US disclosed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 US disclosed
EP-1787985-A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom Unibioscreen S.A. (BE) 2007-05-23 EP disclosed
EP-1787985-A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom Unibioscreen S.A. (BE) 2007-05-23 EP disclosed
WO-2007054292-A2 AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM UNIBIOSCREEN S.A. (BE) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160067241-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS MYC, NME2, TP53 FTO 3395/4885CYP2D6 358/4885HEXA 710/4885
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 FTO 595/4885CYP2D6 796/4885HEXA 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.